Guest edited by Jonathan Kay, this issue of Rheumatic Disease Clinics will cover the latest research and evidence surrounding the diagnosis, treatment and management of rarely seen rheumatic diseases.
Osteoarthritis is the leading cause of disability among older adults affecting upward of 1 in 8 adults. This issue will cover epidemiology, imaging, disease management and modification, and many more topics.
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.
Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.
To ensure the best possible clinical outcomes for arthritis patients, it is essential that they be seen early and treated appropriately at the earliest opportunity. Early therapy has proven much more effective than that given late. This issue of Rheumatic Disease Clinics of North America brings the rheumatologist up to date on the latest treatments and interventions in evolving arthritis and established early arthritis. Topics covered include early rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, oligoarthritis, osteoarthritis, and others. Imaging modalities are addressed as well as various contemporary treatments including biologics.
This issue features internationally renowned experts who have provided their expertise on a variety of topics related to the importance of vitamin D. It was not until feed back loops were identified between Vitamin D production and parathyroid hormone, phosphate that it earned its place as a true endocrine hormone. Current social and economic conditions have brought it back into the limelight with outbreaks of rickets and osteomalacia even in developed countries. However its complex regulation, together with the identification and characterization of the vitamin D receptor and its role in influencing multiple genetic pathways and function has heralded a new era highlighting its importance in health and disease. This includes its role in auto immune diseases such as multiple sclerosis, diabetes mellitus, cancer especially breast and prostate, skin, neurological and cognitive disorders and infectious diseases such as tuberculosis. We now know that adequate levels of vitamin D it is important in preventing falls and fracture. The need for supplementation and the amount recommended has also changed considerably from what we previously considered sufficient. The ongoing development of selective active analogs of vitamin D targeted to specific organs and function leads to the exciting possibility of improving outcomes of diseases associated with vitamin D regulation.
This issue of Rheumatic Disease Clinics of North America provides foundational and in-depth information about paraneoplastic and cancer treatment-related rheumatic disorders, in which every practicing rheumatologist should be well-versed. Topics covered include neoplasm risk in patients with rheumatic diseases; neoplasm risk of anti-rheumatic therapy; rheumatologic laboratory findings in malignancy; rheumatic manifestations of primary and metastatic bone tumors and paraneoplastic bone disease; neoplastic/paraneoplastic synovitis; neoplastic/paraneoplastic dermatitis, fasciitis, and panniculitis; neoplastic/paraneoplastic vasculitis, vasculopathy, and hypercoagulability; neoplastic/paraneoplastic myalgias and myositis; and less-common neoplastic/paraneoplastic syndromes.
This timely and evocative issue of Rheumatic Disease Clinics explores important current and controversial topics in the treatment of osteoporosis. And it answers some tough questions! Here are some examples. How long do I treat my patient? Is there a place for bone turnover markers? How much Vitamin D should I recommend? Controversies around calcium and Vitamin D are explored regarding the coronary risk and pancreatic issues. Emerging therapies are presented, including sclerostin and oral calcitonin. Long-term safety concerns of antiresporptive therapy (ONJ, atypical fracture, would healing) are explained. The utility and limitations of FRAX are covered, as well as Prolia and the RANKL pathway. An update on glucocorticoid induced OP is given. The reader is also brought up to date on men’s health issues and OP. This is an essential issue for any practicing rheumatologist to stay current in the field.